Takeda Pharmaceuticals will focus on announcing advanced tumor pipeline progress and solid tumor pipeline research results at the 2026 European Society of Medical Oncology Conference. The core content is the newly revealed phase III clinical trial data of arcotargotivitecan.

Takeda Pharmaceuticals will focus on announcing advanced tumor pipeline progress and solid tumor pipeline research results at the 2026 European Society of Medical Oncology Conference. The core content is the newly revealed phase III clinical trial data of arcotargotivitecan.